JP2017531038A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531038A5
JP2017531038A5 JP2017538466A JP2017538466A JP2017531038A5 JP 2017531038 A5 JP2017531038 A5 JP 2017531038A5 JP 2017538466 A JP2017538466 A JP 2017538466A JP 2017538466 A JP2017538466 A JP 2017538466A JP 2017531038 A5 JP2017531038 A5 JP 2017531038A5
Authority
JP
Japan
Prior art keywords
compound
formula
salt
pharmaceutical composition
configuration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017538466A
Other languages
English (en)
Japanese (ja)
Other versions
JP6675407B2 (ja
JP2017531038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2015/052944 external-priority patent/WO2016055791A1/en
Publication of JP2017531038A publication Critical patent/JP2017531038A/ja
Publication of JP2017531038A5 publication Critical patent/JP2017531038A5/ja
Application granted granted Critical
Publication of JP6675407B2 publication Critical patent/JP6675407B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017538466A 2014-10-10 2015-10-08 新規5,6−ジヒドロ−4H−ベンゾ[b]チエノ−[2,3−d]アゼピン誘導体 Active JP6675407B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14188494 2014-10-10
EP14188494.0 2014-10-10
PCT/GB2015/052944 WO2016055791A1 (en) 2014-10-10 2015-10-08 Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative

Publications (3)

Publication Number Publication Date
JP2017531038A JP2017531038A (ja) 2017-10-19
JP2017531038A5 true JP2017531038A5 (OSRAM) 2018-11-22
JP6675407B2 JP6675407B2 (ja) 2020-04-01

Family

ID=51842340

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017538466A Active JP6675407B2 (ja) 2014-10-10 2015-10-08 新規5,6−ジヒドロ−4H−ベンゾ[b]チエノ−[2,3−d]アゼピン誘導体
JP2017538467A Withdrawn JP2017531039A (ja) 2014-10-10 2015-10-08 新規5,6−ジヒドロ−4H−ベンゾ[b]チエノ−[2,3−d]アゼピン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017538467A Withdrawn JP2017531039A (ja) 2014-10-10 2015-10-08 新規5,6−ジヒドロ−4H−ベンゾ[b]チエノ−[2,3−d]アゼピン誘導体

Country Status (13)

Country Link
US (6) US10189863B2 (OSRAM)
EP (2) EP3204388B1 (OSRAM)
JP (2) JP6675407B2 (OSRAM)
KR (1) KR20170058921A (OSRAM)
CN (1) CN106852144B (OSRAM)
AU (1) AU2015329789B2 (OSRAM)
BR (1) BR112017005104B1 (OSRAM)
CA (1) CA2957868C (OSRAM)
EA (1) EA201790796A8 (OSRAM)
IL (1) IL250823A0 (OSRAM)
MX (1) MX2017004652A (OSRAM)
SG (1) SG11201701184WA (OSRAM)
WO (2) WO2016055792A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10189863B2 (en) * 2014-10-10 2019-01-29 Pulmocide Limited 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives
JP6694886B2 (ja) 2014-12-18 2020-05-20 プルモシデ リミテド 4,5−ジヒドロ−6H−チエノ[3,2−d]ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス(RSV)感染を治療するためのその使用
EP3324977B1 (en) 2015-07-22 2022-07-13 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
US20170226129A1 (en) 2016-01-15 2017-08-10 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
EA037206B1 (ru) 2016-02-03 2021-02-19 Янссен Сайенсиз Айрлэнд Юси Комбинация для лечения и ослабления rsv инфекции и фармацевтическая композиция на её основе
WO2017175000A1 (en) 2016-04-08 2017-10-12 Pulmocide Limited Compounds
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
CN110809472B (zh) 2017-02-16 2023-05-23 英安塔制药有限公司 用于制备苯二氮䓬衍生物的方法
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2019006295A1 (en) * 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
EP3687543B1 (en) 2017-09-29 2024-03-20 Enanta Pharmaceuticals, Inc. Combinations of pharmaceutical agents as rsv inhibitors
WO2019094903A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
US10647711B2 (en) 2017-11-13 2020-05-12 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as RSV inhibitors
WO2019199908A1 (en) * 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
SG11202110137VA (en) 2019-03-18 2021-10-28 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
WO2020210246A1 (en) * 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
EP4037688A4 (en) 2019-10-04 2023-09-06 Enanta Pharmaceuticals, Inc. ANTIVIRAL HETEROCYCLIC COMPOUNDS
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
UY39642A (es) 2021-02-26 2022-09-30 Enanta Pharm Inc Compuestos heterocíclicos antivirales
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693635A (en) 1993-07-29 1997-12-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
CZ20013834A3 (cs) 1999-04-28 2002-04-17 Aventis Pharma Deutschland Gmbh Deriváty kyselin se třemi arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují
EP2240029A4 (en) * 2008-01-07 2012-08-22 Synta Pharmaceuticals Corp COMPOUNDS FOR USE AGAINST INFLAMMATORY AND IMMUNOMIC DISEASES
WO2011005842A1 (en) 2009-07-09 2011-01-13 Gilead Sciences, Inc. Anti-rsv compounds
KR101804588B1 (ko) 2009-10-13 2017-12-04 리간드 파마슈티칼스 인코포레이티드 조혈 성장 인자 모방체 소분자 화합물 및 이의 용도
KR101764952B1 (ko) 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ampk-활성화 헤테로시클릭 화합물 및 그의 사용 방법
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
RU2017106742A (ru) 2014-08-05 2018-09-06 Элиос Биофарма, Инк. Комбинированная терапия для лечения парамиксовируса
US10189863B2 (en) * 2014-10-10 2019-01-29 Pulmocide Limited 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives
US20170226129A1 (en) 2016-01-15 2017-08-10 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
EA037206B1 (ru) 2016-02-03 2021-02-19 Янссен Сайенсиз Айрлэнд Юси Комбинация для лечения и ослабления rsv инфекции и фармацевтическая композиция на её основе
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors

Similar Documents

Publication Publication Date Title
JP2017531038A5 (OSRAM)
JP2017537949A5 (OSRAM)
JP2009535352A5 (OSRAM)
JP2018021051A5 (OSRAM)
JP2020507589A5 (OSRAM)
JP2016530259A5 (OSRAM)
CY1119880T1 (el) Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων
JP2016525102A5 (OSRAM)
JP2013518107A5 (OSRAM)
JP2017523225A5 (OSRAM)
JP2011528713A5 (OSRAM)
JP2016515561A5 (OSRAM)
JP2013534248A5 (OSRAM)
JP2013508279A5 (OSRAM)
JP2020097577A5 (OSRAM)
JP2017523169A5 (OSRAM)
JP2019526596A5 (OSRAM)
JP2014526554A5 (OSRAM)
JP2007501809A5 (OSRAM)
JP2015521156A5 (OSRAM)
JP2017517565A5 (OSRAM)
JP2019505529A5 (OSRAM)
JP2018527301A5 (ja) アジリジン含有dnaアルキル化剤
JP2019527724A5 (OSRAM)
JP2011513410A5 (OSRAM)